drugset / Trial / NCT05095467
HIPEC-AS in Patients With Peritoneal Metastasis of the Stomach or Esophagogastric Junction
Non-randomizedParallel-groupOpen-labelTreatment
Summary
HIPEC-AS01 is an open, prospective, single-center phase II clinical study, which will include "cT4aNxM0, P0 or cTxNxM1, P1" patients with gastric or esophagogastric junction adenocarcinoma, to evaluate the efficacy and safety of systemic chemotherapy with HIPEC combined with AS in the perioperative period. Patients enrolled will be divided into three groups. Among them, group A is the patients with locally resectable GC; group B is patients with peritoneal metastasis stage P1a or P1b, group C is patients with peritoneal metastasis stage P1c. The primary purpose is to evaluate the 3-year overall survival rate.
Timeline
- Start
- 2021-10
- Primary completion
- 2023-10
- Completion
- 2026-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Paclitaxel | Small molecule | 120 mg/m2 | Other |
| Subject | tegafur-gimeracil-oteracil potassium | Small molecule | 40 mg | Oral |
| Subject | tegafur-gimeracil-oteracil potassium | Small molecule | 60 mg | Oral |